<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02789592</url>
  </required_header>
  <id_info>
    <org_study_id>H-1604-134-757</org_study_id>
    <nct_id>NCT02789592</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Melatonin PR and Clonazepam in Patients With REM Sleep Behavior Disorder in Parkinson Disease</brief_title>
  <official_title>A Randomized Double-Blind, Double-Dummy, Crossover Study to Evaluate the Efficacy and Safety of Prolonged-Release Melatonin and Clonazepam in Patients With Rapid Eye Movement (REM) Sleep Behavior Disorder in Parkinson Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kuhnil Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether melatonin prolonged-release (PR) and
      clonazepam are effective and safe in the treatment of rapid eye movement behavior disorder
      (RBD) of patients with Parkinson's disease (PD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RBD is one of the representative non-motor symptoms of PD. Patients with RBD show
      dream-enacting behaviors such as punching, kicking, singing, screaming, or somnambulism.
      These can interfere in sleep quality and increase the risk of falling down from the bed and
      physical injuries of both the patient and sleep partner. Therefore, qualities of life of the
      patient and sleep partner are negatively influenced by presence of RBD.

      Clonazepam has been used for treatment of choice of RBD. However, the efficacy of clonazepam
      is not proven in the clinical trial. Clonazepam has several side effects that could be
      problematic in PD patients such as increasing fall-down risk, daytime somnolence, and
      cognitive decline. Melatonin is a second-line treatment option for RBD, but there has been
      only one randomized crossover trial that evaluated the efficacy of melatonin on RBD. Finally,
      there has been no study that evaluate and compare the efficacy and safety of melatonin and
      clonazepam for treatment of RBD.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Global Impression-Improvement scale (CGI-I)</measure>
    <time_frame>Four weeks (plus or minus 3 days)</time_frame>
    <description>Clinician assessed rating scale of clinical improvement or worsening relative to a baseline state, scored as 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change of the Clinical Global Impression-Severity scale (CGI-S)</measure>
    <time_frame>Four weeks (plus or minus 3 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression-Improvement scale (PGI-I)</measure>
    <time_frame>Four weeks (plus or minus 3 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change of the Patient Global Impression-Severity scale (PGI-S)</measure>
    <time_frame>Four weeks (plus or minus 3 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>modified RBD Questionnaire-HongKong (mRBDQ-HK)</measure>
    <time_frame>Four weeks (plus or minus 3 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change of the Epworth Sleepiness Scale (ESS)</measure>
    <time_frame>Four weeks (plus or minus 3 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change of the Parkinson Disease Sleep Scale (PDSS)</measure>
    <time_frame>Four weeks (plus or minus 3 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change of the Montreal Cognitive Assessment (MoCA)</measure>
    <time_frame>Four weeks (plus or minus 3 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change of the Unified Parkinson's Disease Rating Scale (UPDRS)</measure>
    <time_frame>Four weeks (plus or minus 3 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep diary</measure>
    <time_frame>Four weeks (plus or minus 3 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>REM Sleep Behavior Disorder</condition>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1: Melatonin PR 2 mg 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 2: Clonazepam 0.5 mg 1 tablet+Melatonin PR placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 3: Melatonin PR placebo 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1: Clonazepam 0.5 mg 1 tablet+Melatonin PR placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 2: Melatonin PR placebo 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 3: Melatonin PR 2 mg 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1: Melatonin PR placebo 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 2: Melatonin PR 2 mg 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 3: Clonazepam 0.5 mg 1 tablet+Melatonin PR placebo 1 tablet, 1/day before sleeping for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1: Melatonin PR 2 mg 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 2: Melatonin PR placebo 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 3: Clonazepam 0.5 mg 1 tablet+Melatonin PR placebo 1 tablet, 1/day before sleeping for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1: Clonazepam 0.5 mg 1 tablet+Melatonin PR placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 2: Melatonin PR 2 mg 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 3: Melatonin PR placebo 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1: Melatonin PR placebo 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 2: Clonazepam 0.5 mg 1 tablet+Melatonin PR placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 3: Melatonin PR 2 mg 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin PR</intervention_name>
    <description>For experimental treatment of RBD</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
    <other_name>Circadin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clonazepam</intervention_name>
    <description>For experimental treatment of RBD</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
    <other_name>Rivotril</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin PR placebo</intervention_name>
    <description>Placebo pill manufactured to mask melatonin PR 2mg tablet</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
    <other_name>Placebo tablet of Melatonin PR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clonazepam placebo</intervention_name>
    <description>Placebo pill manufactured to mask clonazepam 0.5mg tablet</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
    <other_name>Placebo tablet of clonazepam</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject was enrolled voluntarily and understood the contents of this clinical trial

          -  Subject was diagnosed as Parkinson disease (PD)

          -  Hoehn and Yahr (H&amp;Y) stage 1, 2, or 3

          -  Existence of caregivers who can provide a information about symptoms of rapid eye
             movement sleep disorder (RBD) of the participant

          -  RBD frequency is one or more per week

          -  Existence of RBD by answering &quot;yes&quot; to the question (RBD-1Q): &quot;Have you ever been
             told, or suspected yourself, that you seem to 'act out your dreams' while asleep (for
             example, punching, flailing your arms in the air, making running movements, etc.)?&quot;

          -  Good compliance for reporting PGI scores and sleep diary

        Exclusion Criteria:

          -  Existence of cognitive decline hard to participate in the clinical trial

          -  Hypersensitivity to melatonin or clonazepam

          -  Previous melatonin or clonazepam treatment within 1 month

          -  Changing anti-parkinsonian medications within 1 month

          -  Current treatment with sedatives or hypnotics at bedtime

          -  Diagnosed as epilepsy or current treatment with anti-epileptic drugs

          -  Severe trauma history due to RBD

          -  Lactating, pregnant, or possible pregnant

          -  Subject has confusion or visual hallucination in daytime

          -  Diagnosed as obstructive sleep apnea or severe snoring

          -  Diagnosed as other parasomnia

          -  Presence of severe psychiatric illness

          -  Alcoholics or drug abuser

          -  Myasthenia gravis

          -  Acute narrow-angle glaucoma

          -  Prior participation to other clinical trials within 3 months

          -  Presence of severe comorbidities or a cancer

          -  Existence of illness or problems which makes difficult to be enrolled to this trial
             judged by clinicians
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beomseok Jeon, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Beomseok Jeon, MD, PhD</last_name>
    <email>brain@snu.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chae Won Shin, MD, MSc</last_name>
    <email>chroma0202@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Arnulf I. REM sleep behavior disorder: motor manifestations and pathophysiology. Mov Disord. 2012 May;27(6):677-89. doi: 10.1002/mds.24957. Epub 2012 Mar 22. Review.</citation>
    <PMID>22447623</PMID>
  </reference>
  <reference>
    <citation>Sixel-Döring F, Trautmann E, Mollenhauer B, Trenkwalder C. Associated factors for REM sleep behavior disorder in Parkinson disease. Neurology. 2011 Sep 13;77(11):1048-54. doi: 10.1212/WNL.0b013e31822e560e. Epub 2011 Aug 10.</citation>
    <PMID>21832215</PMID>
  </reference>
  <reference>
    <citation>Kunz D, Mahlberg R. A two-part, double-blind, placebo-controlled trial of exogenous melatonin in REM sleep behaviour disorder. J Sleep Res. 2010 Dec;19(4):591-6. doi: 10.1111/j.1365-2869.2010.00848.x.</citation>
    <PMID>20561180</PMID>
  </reference>
  <reference>
    <citation>Schenck CH, Montplaisir JY, Frauscher B, Hogl B, Gagnon JF, Postuma R, Sonka K, Jennum P, Partinen M, Arnulf I, Cochen de Cock V, Dauvilliers Y, Luppi PH, Heidbreder A, Mayer G, Sixel-Döring F, Trenkwalder C, Unger M, Young P, Wing YK, Ferini-Strambi L, Ferri R, Plazzi G, Zucconi M, Inoue Y, Iranzo A, Santamaria J, Bassetti C, Möller JC, Boeve BF, Lai YY, Pavlova M, Saper C, Schmidt P, Siegel JM, Singer C, St Louis E, Videnovic A, Oertel W. Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy--a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group. Sleep Med. 2013 Aug;14(8):795-806. doi: 10.1016/j.sleep.2013.02.016. Epub 2013 Jul 22. Erratum in: Sleep Med. 2014 Jan;15(1):157.</citation>
    <PMID>23886593</PMID>
  </reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2016</study_first_submitted>
  <study_first_submitted_qc>June 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2016</study_first_posted>
  <last_update_submitted>June 2, 2016</last_update_submitted>
  <last_update_submitted_qc>June 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>BS Jeon</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>REM Sleep Behavior Disorder</keyword>
  <keyword>Parkinson Disease</keyword>
  <keyword>Randomized Controlled Trial</keyword>
  <keyword>Clinical Trial</keyword>
  <keyword>Melatonin</keyword>
  <keyword>Clonazepam</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>REM Sleep Behavior Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
    <mesh_term>Clonazepam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

